We currently offer Paxlovid (nirmatrelvir; ritonvir) as the recommended first-line agent. When Paxlovid is not feasible due to contraindications and/or major drug interactions, we also offer oral molnupiravir. For monoclonal antibody therapy, we will no longer be using bebtelovimab because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1.
Information, fact sheets, and order form templates can be found to the right.
Please access the survey link below to choose your preferred COVID-19 treatment option.
(Please Note–The survey link above is only for Nursing Home and Assisted Living Residents)
For any questions regarding monoclonal antibodies, Paxlovid, Molnupiravir or the request process, please contact Danny Schroeder at email@example.com or Mounica Soma at firstname.lastname@example.org